Home
News
Videos
Podcasts
Menu
Акционерное общество "ТВ БРИКС"
tvbrics@tvbrics.com
Рубцов переулок, д.13, Москва, 105082, RU
+74996425304
Currencies:
RUB/USD 0,0124
0,0000
BRL/USD 0,1959
0,0013
INR/USD 0,0105
0,0000
CNY/USD 0,1479
0,0004
ZAR/USD 0,061
0,0004
IDR/USD 0,0001
0,0000
SPACE FOR MEDIA DIPLOMACY
10:30 «City of stories»
10:30 «City of stories»
Now 16+
10:30

«City of stories»

It is indicated Moscow time in the programme. Please take into account the time difference with your time zone.
11:00 «BRICSreport»
Next
11:00

«BRICSreport»

16+
11:15

«BRICSterview»

16+
11:45

«Laboratorium»

16+
Menu
Broadcast «City of stories»
RUB/USD
0,0124
0,0000
BRL/USD
0,1959
0,0013
INR/USD
0,0105
0,0000
CNY/USD
0,1479
0,0004
ZAR/USD
0,061
0,0004
IDR/USD
0,0001
0,0000
TV BRICS Apps
Indian scientists develop breakthrough nanoformulation for safer Parkinson’s treatment

This innovative nanoformulation prevents mitochondrial damage by inhibiting the translocation of calpain

Indian researchers have unveiled a groundbreaking nanoformulation designed to enhance the safety and effectiveness of Parkinson’s disease treatment. This is reported by IANS, a partner of TV BRICS.

The group of scientists has developed a targeted drug delivery system that enables the sustained release of 17β-oestradiol (E2), a hormone essential for managing Parkinson’s symptoms.

Parkinson’s disease, a progressive neurodegenerative disorder, is linked to an imbalance of 17β-oestradiol in the brain. However, the widespread use of this hormone in therapy has been limited due to its potential side effects and an incomplete understanding of its molecular mechanisms. To address these challenges, researchers have utilised dopamine receptor D3 (DRD3)-conjugated chitosan nanoparticles to precisely deliver 17β-oestradiol to the brain, significantly improving its therapeutic potential.

This innovative nanoformulation prevents mitochondrial damage by inhibiting the translocation of calpain.

The study further revealed a breakthrough in understanding the role of BMI1, a key regulator of mitochondrial homeostasis, in Parkinson’s disease, the source claims. The nanoformulation successfully restored BMI1 expression by preventing its degradation through calpain inhibition, highlighting a new potential target for neuroprotective therapies.

Photo: iStock